share_log

Reunion Neuroscience (TSE:REUN) Stock Rating Reaffirmed by HC Wainwright

Defense World ·  Jan 21, 2023 01:21

Reunion Neuroscience (TSE:REUN – Get Rating)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a research report issued on Thursday. They presently have a C$20.00 target price on the stock.

Separately, Roth Capital initiated coverage on Reunion Neuroscience in a research report on Friday, December 16th. They set a "buy" rating and a C$11.00 target price on the stock.

Get Reunion Neuroscience alerts:

Reunion Neuroscience Stock Performance

Shares of TSE:REUN opened at C$1.77 on Thursday. Reunion Neuroscience has a 52-week low of C$1.08 and a 52-week high of C$13.10.

About Reunion Neuroscience

(Get Rating)

Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions.

Recommended Stories

  • MarketBeat Week in Review – 1/16 – 1/20
  • Does Old Dominion Show That Trucking Is Hitting The Brakes?
  • Nordstrom Puts Fear Of Markdowns Into Retail Sector
  • Exxon Mobil Stock: Within Striking Distance Of Buy Point
  • High-Dividend-Yielding BHP Sees China Driving '23 Growth

Receive News & Ratings for Reunion Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reunion Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment